StatPearls, LLC

  • Diabetes, Gestational
  • Diabetic Ketoacidosis
  • Hyperglycemic Hyperosmolar Nonketotic Coma
  • Insulin
  • Insulin Lispro

Insulin Lispro

Insulin lispro, an FDA-approved insulin analog, is an effective treatment for regulating hyperglycemia in type 1 and 2 diabetes. This medication extends its utility beyond its primary indication, finding application in off-label uses such as managing mild-to-moderate diabetic ketoacidosis, gestational diabetes, and mild-to-moderate hyperosmolar hyperglycemic state. The potency of insulin lispro stands at parity with human insulin, with each unit demonstrating equivalent efficacy in lowering glucose levels. This activity covers their mechanisms, adverse event profiles, eligible patient populations, drug interactions, and monitoring. The content underscores the significance of rapid-acting insulin, particularly insulin lispro, in optimizing patient outcomes within diabetes care.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 1.5 creditsAAPA Category 1 Credit™Up to 1.5 creditsAMA PRA Category 1 Credit™Up to 1.5 creditsNursingUp to 1.5 creditsPharmacyUp to 1.5 credits

MOC types

ABS — Accredited CMEUp to 1.5 pointsABOS — Accredited CMEUp to 1.5 pointsABPATH — Lifelong LearningUp to 1.5 pointsABA — Lifelong LearningUp to 1.5 pointsABTS — Accredited CMEUp to 1.5 pointsABIM — Medical KnowledgeUp to 1.5 pointsABS — Self-AssessmentUp to 1.5 pointsABP — Lifelong Learning and Self-AssessmentUp to 1.5 pointsABTS — Self-AssessmentUp to 1.5 points

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Cross-Specialty

Relevant across 11 specialties.

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 1.5 credits
  • MOC · Up to 1.5 points
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left